Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Patient safety

Women taking valproate should be told about risks of developmental disorders in offspring

Women taking valproate should be told about the risks of developmental disorders in children exposed to the drug during pregnancy, says the UK medicines regulator.

The call follows the strengthening of product information for valproate-containing medicines after a 2014 European review found that up to 40% of children born to women who take valproate during pregnancy may have such disorders, including delayed walking and talking, memory problems, difficulty with speech and language and lower intellectual ability.

“We want to ensure that medical professionals inform women and girls of the latest information about the risks of developmental disorders in children exposed to valproate during pregnancy, in addition to the already well-known risks of birth defects,” says June Raine, director of the Medicines and Healthcare products Regulatory Agency’s vigilance and risk management of medicines division.

In line with advice from the European Medicines Agency, the MHRA says that if valproate is the only treatment option, women of childbearing age should be given effective contraception. Women taking valproate must also have regular reviews of their treatment. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067644

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.